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 1. Introduction 
Osteonecrosis of the jaw is a well-known, 
severe side effect of bisphosphonate (BP) 
treatment, and was first reported as a rare but 
serious complication 3 decades ago (Marx, 
2003; Wang et al., 2003). BPs are anti-bone 
resorptive drugs used routinely to 
decrease osteoclast-mediated bone loss in 
osteoporosis, multiple myeloma, Paget disease, 
and complications of metastatic disease. A 
high percentage of bisphosphonate-related 
osteonecrosis of the jaw (BRONJ) cases have 
been reported in patients treated with high doses 
of intravenous aminobisphosphonate (mainly 
zoledronic or pamidronic acid). An increased 
risk of BRONJ has been reported in 
intravenously treated cancer patients (odds ratio 
[OR] ¼ 4.27) compared to those treated orally 
(OR ¼ 1.18) (Lee et al., 2014). These 
patients often receive concomitant treatment 
with immunosuppressive and/or chemotherapy 
drugs, increasing the risk of osteonecrosis 
(Ruggiero et al., 2009; Anavi-Lev et al., 2013). 
Other risk factors include invasive dental 
procedures, oral infections, mechanical 
trauma to the jawbone, and long-term BP 
treatment (Dodson, 2009; Kuhl et al., 2012). 
In addition to its low incidence, the main 
challenges of this complication are the limited 
knowledge of its pathogenesis and the 
absence of effective established treatment. 
These difficulties have led several research 
teams to explore new therapeutic strategies for 
treatment and prevention of BRONJ disease. 
Mucosal coverage of alveolar sockets after 
dental extractions has been performed as 
treatment (Voss et al., 2012) and as a preventive 
measure (Abtahi et al., 2013) in order to avoid 
bacterial contamination and to increase blood 
supply to BP-affected bone during the 
healing process. Defective bone healing occurs 
in BRONJ because of suppressed bone turnover, 
likely favored by the antiangiogenic properties 
of potent BPs such as zoledronic acid (ZA) 
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(Yamada et al., 2009; Anavi-Lev et al., 2013; 
Sharma et al., 2013). Therefore, it 
seems that stimulating angiogenesis locally 
could be an effective management strategy. 
Mesenchymal stem cells (MSCs) have 
recently emerged as candidates for BRONJ 
treatment (Kikuiri et al., 2010; Cella et al., 
2011; Gonzalvez-Garcia et al., 2013; Li et al., 
2013) due to their capacity to differentiate to 
other mesenchymal tissues 
such as bone, cartilage, and adipocytes 
(Pittenger et al., 1999), and 
due to the secretion of numerous cytokines with 
immunomodulatory and proangiogenic activity. 
Although the mechanisms of the 
immunosuppressive effects of MSCs have not 
been clearly defined, it seems that MSCs 
modulate the function of different cells involved 
in immune response (Yoo et al., 2009; Kikuiri et 
al., 2010; Li et al., 2013) and tissue healing. 
MSCs have also been reported to be 
immunoprivileged cells, without human 
leukocyte antigen (HLA)e II expression and 
limited expression to HLA-I, a relevant feature 
since it would allow their allogeneic 
transplantation. Currently, allogeneic MSCs are 
used in different clinical trials (89 clinical trials 
registered on clinicaltrials.gov); no adverse 
events have been reported 
to date. 
Adipose tissue is an abundant and easily 
accessible source of MSCs, known as adipose-
derived stem cells (ASCs). ASCs have been 
widely studied since they were first described in 
2001 (Zuk et al., 2001), and have shown great 
potential in enhancing wound healing 
(Toyserkani et al., 2014). Bone-inducing 
substances such as bone morphogenetic protein 
2 (BMP-2) have been used to culture 
MSCs for treatment of skeletal defects and bone 
diseases by promoting their differentiation to 
bone tissue (Cowan et al., 2005). 
Another emerging treatment that has been used 
in BRONJ is platelet-rich plasma (PRP). 
Although only a small number of 
observational studies have been performed to 
investigate their effects, the positive results 
seem to be related to growth-factor as 
well as cytokine secretion that stimulate healing 
(Martins et al., 2012; Longo et al., 2014; 
Mathias Duarte et al., 2014; Sarkarat 
et al., 2014). In addition, investigators in new 
experimental studies are searching for 
regenerative properties in the combination 
of MSCs with PRP, promoting MSC function 
because of the great amount of substances 
released by activated platelets (Van 
Pham et al., 2013). Research into bone 
regeneration is focused on osteoblastic potential 
differentiation (Pak, 2012; Tajima et al., 2014). 
No well-established models have been 
published in which the effectiveness of both 
PRP and MSCs are tested in BRONJ treatment. 
Faced with the adverse situation of a lack of 
established preventive 
treatment for BRONJ after dental extractions 
together with suboptimal 
current treatments, we aimed to compare the 
effectiveness of different emerging therapies in 
preventing BRONJ development 
by using a rat model with dental extractions. To 
accomplish this, we studied the local application 
of different combinations of ASCs with 
and without previous stimulation with BMP-2 
and PRP in rats. 
2. Material and methods 
2.1. Study design 
A rat model was chosen to test four different 
treatments applied after dental extractions in 
bisphosphonate-treated animals; to do 
this, we followed our previously published 
BRONJ-like disease model (Barba-Recreo et al., 
2014), which replicates the histologic 
and radiographic findings of the human disease. 
Following this BRONJ model, the 
bisphosphonate chosen was ZA because of its 
high relative potency. 
The present study was approved by the Ethical 
Committee for 
Animal Care of the University Hospital La Paz, 
Madrid, Spain. It was conducted in accordance 
with the European Union guidelines for 
experimental animal use. Fifty-six adult male 
Wistar rats (Charles Rivers, France) with an 
average age of 8 weeks (mean weight 350 g) 
were used in this study. The animals were kept 
in an environment with a controlled 
temperature and 12-hour lightedark cycles, with 
food and water supplied ad libitum. 
All animals received intraperitoneal ZA 
(Zometa 0.1 mg/kg, Novartis Pharma AG, 
Basel, Switzerland) three times a week for a 
period of 9 weeks. Extractions of the three right 
upper molars in each animal were performed in 
the eighth week of treatment (Barba-Recreo et 
al., 2014). 
Oral surgery was carried out under general 
anesthesia (inhaled sevoflurane, 2 mL/min with 
oxygen 1 L/min) with the animal in 
supine position, with the assistance of an optical 
microscope. Tramadol 0.075 mg/kg was 
administrated subcutaneously each day for 
the first 3 postoperative days. 
The animals were randomly assigned into four 
groups as follows. 
In group 1 (n ¼ 14), animals were treated with a 
buccal mucoperiosteal flap to cover the alveolar 
bone postextractions. Light subperiosteal 
debridement and advancement of the buccal 
mucosa 
were performed. Gingival borders were attached 
with a 6/0 silk continuous suture, covering the 
defect without tension. 
In group 2 (n ¼ 14), animals were treated with 
allogeneic PRP applied over the alveolar 
sockets after dental extractions. The same 
mucoperiosteal flap as in group 1 was 
performed to retain and cover the PRP clot over 
the maxillary alveolar bone. 
In group 3 (n ¼ 15), animals were treated with 
allogeneic ASCs. 
One million ASCs included in a PRP clot were 
applied over the alveolar sockets. The 
aforementioned mucoperiosteal flap was used 
to retain the ASCs with PRP in the area of 
interest (Fig. 1). 
In group 4 (n ¼ 13), animals were treated with 1 
million ASCs cultured with BMP-2 applied over 
the alveolar sockets. A PRP clot 
and a mucoperiosteal flap affixed over the clot 
were used as covering layers. 
One week after dental extractions, the animals 
were killed by decapitation while under general 
anesthesia (inhaled isoflurane with oxygen 3 
L/min). The heads were harvested for further 
histologic, fluorescence, and radiologic studies. 
2.2. PRP preparation Allogeneic PRP was 
obtained from the blood of 3 healthy donor 
Wistar rats by intracardiac puncture (2 mL 
blood collected perdonor animal) under general 
anesthesia (inhaled isoflurane with 
oxygen 3 L/min) and stored in sodium citrate 
tubes. The tubes were centrifuged for 10 min at 
3500 rpm at room temperature. The first 
500 mL of plasma (platelet-poor fraction) of 
each tube was discarded, and 450 mL of plasma 
from the closest region to the buffy coat was 
collected, avoiding cell collection. Aliquots 
(100-mL) of PRP were prepared and frozen at 
20                                                           C until 
use. 
For clot formation, aliquots of PRP were 
defrosted, and 1.5 mL of 
CaCl2 dissolved in deionized water at a 
concentration of 2.3 mg/mL 
(10%) was added to each 25 mL of PRP. 
Aliquots of the final volume measuring 26.6 mL 
each were incubated for 3e5 min at 37 
                                                          C until a 
manageable clot was obtained. These clots were 
later applied over 
the alveolar sockets (group 2 animals) within 
20e30 min after activation. 
For group 3 (PRP with ASCs), PRP was 
prepared as described 
above. After centrifugation of the ASCs at 1,500 
rpm, 1 million cells were resuspended in a 
previously generated aliquot of PRP prior to 
clot formation by incubation at 37 
                                                          C. 
In group 4, ASCs with BMP-2 were not applied 
in a PRP clot due to BMP-2 interference with 
the CaCl2 during the clot activation. 
ASCs with BMP-2 (1 million cells suspended in 
25 mL of saline) were 
applied over the alveolar sockets and covered 
with a PRP clot in the same fashion as in group 
2. 
2.3. ASC isolation, cell culture, 
characterization, and labeling 
Allogeneic ASCs were obtained from the 
subcutaneous fat tissue 
of three female donor Wistar rats (the same 
donor animals used for PRP preparation) 
according to a previously described protocol in 
humans, with minor modifications (Zuk et al., 
2001). Fat tissue was ground into small pieces 
and digested with type I collagenase 
(0.075%; Gibco BRL, Paisley, Scotland, UK). 
The collagenase was then inactivated by the 
addition of an equal volume of Dulbecco's 
modified Eagle's medium (DMEM; Gibco 
BRL), which contained 10% of fetal bovine 
serum (FBS; Gibco BRL). The digested tissue 
was centrifuged at 250 g for 10 min, and the 
pellet was resuspended in 0.16 M NH4Cl for 
erythrocyte lysis. After filtering through a 70-
mm nylon mesh, the cells were plated in culture 
dishes and cultured at 37 
                                                          C in a 
humid atmosphere with 5% carbon dioxide in 
the DMEM (Gibco BRL) containing 10% FBS 
(Gibco BRL) and 1% penicillinestreptomycin 
(Gibco BRL). The medium was changed to 
remove nonadherent cells 24 h after seeding, 
and every 3e4 days thereafter. For subculturing, 
cells were detached with 0.05% (v/v) 
trypsineethylenediaminetetraacetic acid (EDTA; 
Gibco BRL) in 
 
 
 
 
Fig. 1. (A) Adipose-derived stem cells in platelet-rich plasma clot 
covering alveolar 
sockets after molar extractions in a rat from group 3. (B) Coverage of 
alveolar sockets 
with the mucoperiosteal flap and 6/0 silk continuous suture. 
 
 
phosphate-buffered saline when 70%e80% 
confluencewas reached. 
In the third subculture, when 60%e70% 
confluence was reached, all cells were frozen 
until the week before their use. 
For characterization of ASCs, cell cultures were 
analyzed by fourcolor flow cytometry using a 
FACSCalibur flow cytometer (Becton 
Dickinson Biosciences, San Jose, CA, USA) 
after staining with fluorochrome-conjugated 
monoclonal antibodies. The following 
conjugated antibodies were used at saturating 
quantities: Alexa Fluor 647econjugated CD90, 
CD29, CD45, and CD11b (Serotec, 
Spain). Briefly, 2 
                                                                               
105 nucleated cells were incubated for 20 min at 
room temperature with the above-mentioned 
antibodies. Data 
acquisition and analysis were performed using 
the CELLQuest PRO software program (Becton 
Dickinson Biosciences, San Jose, CA, 
USA). 
Once thawed, the cells were cultured for 1 week 
and, prior to implantation, ASCs were marked 
with PKH-26 (SigmaeAldrich, St 
Louis, MO, USA) following the protocol of the 
manufacturer, for groups 3 and 4. 
For group 4, ASCs were cultured with 1 mg/mL 
BMP-2 (Noricum SL, Madrid, Spain) for 10 
days, with the medium being renewed 
each 4 days under standard conditions. 
One million allogeneic ASCs were applied in 
each maxilla in groups 3 and 4 according to the 
protocol described in the section on 
PRP preparation. 
2.4. Macroscopic analysis 
Mucosa healingwas assessed visually as either 
bone exposure or complete mucosa healing. 
2.5. Sample preparation 
The rat heads were fixed with 4% formaldehyde 
and sectioned sagittally with an electric metal 
saw. Plane radiographs (PHILPS Diagnostic 93) 
were taken of each half-head. Samples were 
then decalcified with nitric acid over 72 h. The 
half-jaws were harvested en bloc. Alveolar bone 
was sectioned sagittally with a scalpel in 
buccal and palatal/lingual fragments. Blocks of 
each half-jaw were placed in 70% ethanol and 
further dehydrated in graded alcohol 
solutions and embedded in paraffin. Histologic 
sections (5- to 6-mm thick) of each alveolar 
process were cut along the mesiodistal plane 
and stained with hematoxylineeosin and 
trichrome. 
2.6. Histologic analysis and cell tracing 
Histologic analysis was performed by a 
pathologist in blinded 
fashion (light microscopy, 
                                                                              
40 magnification). 
Several histologic parameters were evaluated, as 
follows. (1) 
Osteonecrosis or necrotic foci, defined as 8 to 
10 adjacent empty lacunae in the alveolar bone, 
as previously described by Enlow and 
Yamashita (Basi et al., 2011; Yamashita et al., 
2011); (2) osteoclast counting: arithmetic mean 
of their count in three different fields 
(
                                                                              
40), in two different random cuts in the alveolar 
process of upper 
jaw; (3) vascularization. evaluated at the level 
of the alveolar processes 
of the upper jaw and graded according to a 
visual scale from 1 to 5 (1 ¼ absence of vessels, 
5 ¼ duplication of the vascular surface 
area compared to this area in rats with no ZA 
treatment (reference group from our previous 
study (Barba-Recreo et al., 
2014))); and (4) degree of alveolar bone 
remodeling (after tooth extraction), using scale 
from 1 to 5 (1 ¼ absence of bone resorption, 
5 ¼ 100% of alveolar bone area resorbed and 
substituted with fibrous tissue and new 
trabeculae). 
Fluorescence analysis was performed for cell 
tracing. Sections were viewed under a 
fluorescent microscope (Leica DMI6000B 
Wetzalar, Germany). The sections obtained 
from groups 1 and 2 (no 
ASCs applied) were used as negative controls. 
2.7. Radiographic analysis 
Two maxillofacial surgeons evaluated the 
radiographs in a blinded fashion. Bone density 
was assessed by using the radiographic 
densitometric value of healthy post-extracted 
bone as a reference, as shown in our established 
BRONJ rat model (Barba- 
Recreo et al., 2014). Findings suggestive of 
osteonecrosis were defined as osteosclerosis, 
thickening and disorganization of the 
medullary trabeculation, and cortical disruption 
in the right upper jaw. 
2.8. Statistical analysis 
Qualitative variables were analyzed using the 
Pearson c2 test and Fisher exact test. 
Quantitative variables were analyzed with 
nonparametric KruskaleWallis test or 
ManneWhitney U test. The 
statistical significance level was set at 0.05. 
Analyses of the data were performed with the 
program SPSS v. 11.5 (SPSS Inc., Chicago, 
IL, USA). 
3. Results 
3.1. Macroscopic results 
None of the animals showed bone exposure at 
the extraction sites. 
3.2. Histologic results 
One specimen from group 1 and three 
specimens from group 2 were excluded from the 
final analysis due to technical problems 
with the histology, mainly with cutting samples. 
Osteonecrosis foci were found in 54% of 
animals in group 2 and in 46% of animals in 
group 1, contrasting with lower incidence in 
group 3 (20%) and group 4 (8%) treated with 
ASCs. The mean value of osteoclasts was 
higher in group 4 (9.9 osteoclasts per field 
at 
                                                                              
40) and group 3 (8.4 osteoclasts per field at 
                                                                              
40) than in the rest of groups (7.4 osteoclasts 
per field at 
                                                                              
40 in group 2, and 7.2 osteoclasts per field at 
                                                                              
40 in group 1). Vascularity analysis showed a 
high blood vessel count in group 4 (mean 2.5); 
this number decreased in group 3 (2.1), group 2 
(2.3), and group 1 (2.2). 
Nevertheless, alveolar bone remodeling analysis 
showed greater resorption in group 3 (mean 3.2) 
compared with the rest of groups (2.6 in group 
4, 2.8 in group 2, and 1.9 in group 1). 
Incomplete epithelial healing was more frequent 
in group 3 (60%) 1 week after the surgery. 
Small abscesses were found in close relation to 
impacted food and suture remains in the 
submucosa; these were more frequent in group 4 
(54%). Histologic results are summarized in 
Table 1 and Fig. 2. 
The original design of the four groups brought 
an analysis of limited potency due to the low 
number of animals in each group. 
Therefore, we compared the treatments with and 
without ASCs at dental extraction sockets in 
ZA-treated rats (Table 2). 
Osteonecrosis in alveolar bone was present in 
50% of the animals without ASC treatment. 
This percentage decreased to 14% in animals 
treated with allogeneic ASCs. This difference 
was statistically significant (p ¼ 0.007). The 
difference in osteoclast count between groups 
treated with ASCs (9.0 osteoclasts per field 
                                                                               
40) and animals without ASC treatment (7.3 
osteoclasts per field 
                                                                               
40) were also statistically significant (p ¼ 
0.045). It was not possible to estimate 
significant differences during the vascularity 
analysis (2.2 in the group not treated with 
ASCs, and 2.3 in the ASC-treated group). Bone 
resorption was higher in the ASC-treated group 
(2.9). When compared to the animals not treated 
with ASCs, the difference in bone remodeling 
observed at healing alveolar sockets 
(2.3) was statistically significant (p ¼ 0.024). 
Disruption at the mucosal surface and 
inflammatory infiltrates were found more often 
in specimens from ASC-treated rats (43%), 
although no significant difference with non-
ASC-treated group (32%) was found. 
3.3. Fluorescence results 
ASCs were observed fully packed in the PRP 
clot remains 1 week after dental extractions in 
group 3. Furthermore, the cells were found 
throughout the whole alveolar socket in groups 
3 and 4, from the submucosal area down to the 
bottom of the alveolar socket and the new 
trabecular bone (Fig. 3). No ASCs were located 
in the mucosa or in the alveolar bone. 
3.4. Radiographic results 
Plane radiograph analysis showed BRONJ 
features, including 
osteosclerosis, bone thickening, and cortical 
disruption of alveolar bone (Fig. 4 and Table 3). 
Bone density analysis showed osteosclerosis in 
more than 85% of the rats in each group, a 
common consequence of BP treatment. 
Bone thickening was more frequent in group 2 
(54%) and group 3 (47%). Nevertheless, cortical 
disruption of alveolar bone in the upper jaw was 
higher in group 1 (38%). It was not possible to 
estimate significant differences among the 
radiologic findings, either for the original four-
group comparison or for the ASC/non-ASC 
group analysis. 
4. Discussion 
In order to lower the risk of BRONJ after 
traumatic injuries including dental extractions, 
several treatments are gaining popularity among 
oral surgeons, ranging from simple procedures 
such as mucosal flaps, to more sophisticated 
ones such as PRP and stemcell applications. In 
the present work, we showed that adding ASCs 
could further decrease BRONJ incidence in a 
BRONJ high-risk model in rats, compared to 
non-ASC treatments (PRP and mucosal flap), 
with statistical significance. In order to not 
interfere with the immunological properties of 
the studied treatments (PRP and ASCs) and to 
allow us to better analyze the results without 
confounding factors, no other drugs were used 
(e.g., corticoids) to increase BRONJ incidence. 
Some authors defend the use of local flaps, 
especially for resistant cases, in advanced stages 
of disease (Williamson, 2010; Voss 
et al., 2012), or for preventive reasons (Abtahi 
et al., 2013). For our experimental study, we 
chose a mucoperiosteal flap as a standard local 
preventive treatment after dental extractions. 
When the flap was the only measure applied, 
BRONJ incidence decreased from 80% (Barba-
Recreo et al., 2014) to 46% in the present 
model. 
However, the percentage of BRONJ in animals 
treated with high doses of ZA remains too high 
to recommend the flap alone as a sufficient 
preventive treatment following dental 
procedures. PRP is also an emerging BRONJ-
preventive (Scoletta et al., 2011) and treatment 
method (Bocanegra-Perez et al., 2012; Mozzati 
et al., 2012), and has been used in clinical 
practice in a more empirical fashion than based 
on higher scientific evidence. Platelets secrete 
several growth factors and cytokines that could 
decrease and shorten initial local inflammation, 
stimulate neoangiogenesis, and therefore 
promote tissue healing (Marx, 2004). PRP clot 
also seems to be less favorable to bacterial 
growth due to its pH values (Marx, 2004). 
Platelets release almost 95% of their 
presynthesized growth factors within the first 
hour of their activation and continue 
producing these proteins until their senescence 
(5e10 days). 
Therefore, the influence of PRP over bone 
healing, which is a slow process, seems to be 
concentrated exclusively at the beginning of the 
process, and other long-lasting treatments are 
thought to be more beneficial. This observation 
could explain why, in our model, PRP does not 
seem to add benefits (no significance) over the 
flap alone. ASCs are MSCs obtained from 
adipose tissue (Zuk et al., 2001) and are capable 
of secreting a great variety of growth factors 
(Salgado et al., 2010) with a significant impact 
on tissue regeneration (Tsuji et al., 2014). 
Endothelial lineage cell recruitment by MSCs 
could potentially play an interesting role in 
improving the vascular supply (Chen et al., 
2008). A significant number of MSCs grafted 
into the wound can result in the augmentation of 
the local blood supply and improvement of 
regeneration capacity (Cella et al., 2011), and 
subsequently could allow for better osteogenesis 
of the damaged bone (Gonzalvez-Garcia et al., 
2013). We found that animals treated with stem 
cells showed a lower rate of osteonecrosis 
(14%; Table 2) and higher osteoclast density 
(Table 2) (p ¼ 0.007 and p ¼ 0.045, 
respectively). Consequently, bone remodeling 
was increased in stem celletreated specimens 
(p ¼ 0.024). Nevertheless, no significance was 
observed during vascularity analysis. MSCs also 
have unique immunomodulatory properties 
(Nauta and Fibbe, 2007; Wolf and Wolf, 2008). 
 
This activity is thought to be largely based on 
inhibition of T-cell and B-cell proliferation and 
dendritic cell maturation (Nauta and Fibbe, 
2007) and the secretion of a large number of 
cytokines and growth factors (Chen et al., 
2008). MSCs also are able to restore the 
immunologic imbalance produced by zoledronic 
treatment (between T helper cells and regulatory 
T-cells), which may alter the inflammatory 
response of alveolar socket healing in ZA-
treated animals (Kikuiri et al., 2010; Li et al., 
2013). However, in our study, inflammatory 
infiltrates were detected in animals of all 
groups, with no close relation with 
osteonecrosis foci. No adverse reaction against 
allogeneic ASCs or PRP was observed. 
Although autologous PRP use is the most 
 
 
 
Fig. 3. Fluorescence study in an animal from group 3. (A) Adipose-
derived stem cells (ASCs) labeled with PKH-26 (red fluorescence) located 
at submucosa. (m, mucosa). (B) ASCs located within the whole alveolar 
socket. (*crestal bone). (C) ASCs located within new bone trabeculae 
(nb). 
common form of PRP used in humans, 
allogeneic PRP use in small animals makes it 
possible to obtain a large amount of this product 
from few donor animals (Rajabi et al., 2015). 
ASCs have a great advantage over bone marrow 
mesenchymal stem cells (BM-MSCs) in terms 
of cell yield. Both types of MSCs seem to have 
similar properties. However, ASCs are 
characterized by faster cell proliferation, stable 
population doubling, and lower levels of 
senescence than BM-MSCs. Some papers 
describe inferior osteogenic but superior 
angiogenic capacity of ASCs over that of 
BM-MSCs (Liao and Chen, 2014). ASCs have 
been shown to survive in ischemic 
environments and to increase secretion of 
growth factors (VEGF, HGF, and bFGF) that 
are necessary for angiogenesis under hypoxic 
conditions (Rehman et al., 2004; Lee et al., 
2009). 
This fact is interesting for treatment of bone 
osteonecrosis and ischemic wounds as in 
BRONJ. Basic studies have found important and 
synergic effects between PRP and MSCs (Van 
Pham et al., 2013). Both PRP and MSCs 
stimulate macrophage recruitment and shorten 
the acute inflammatory response, which leads to 
early progress to chronic inflammation and 
tissue regeneration (Georgiev-Hristov et al., 
2012). In our study, we used PRP clot for 
packing and retaining the ASCs transplanted in 
group 3, as PRP is an osteoconductive agent that 
provides stability and adhesion to ASCs. This 
combination decreased BRONJ incidence 
compared to mucosal flap and increased bone 
turnover. The paradoxically high percentage of 
mucosal disruption observed in the histologic 
analysis in group 3 could be explained by 
mucosal slight dehiscence favored by the large 
volume of PRP-ASC clot, although PRP and 
submucosa continued covering the bone on the 
seventh day after the oral surgery. It was found 
that PRP seems to decrease VEGF 
 
 
 
 
secretion of ASCs in PRP-cultured cells (Van 
Pham et al., 2013). This fact could explain the 
difference in bone vascularization between 
groups 3 and 4. In group 4, ASCs cultured with 
BMP-2 were directly spread over alveolar 
sockets and covered with a PRP clot, which 
might have less direct influence over the ASCs. 
In order to enhance the osteogenic capacities of 
the ASCs, we introduced BMP-2, as this protein 
has been reported to be an osteogenic enhancer 
(Cowan et al., 2005) and PRP has been 
described as an enhancer of osteoblastic 
differentiation in the presence of BMPs 
(Tomoyasu et al., 2007). With this combination, 
we achieved the lowest incidence of BRONJ. 
This group also had the highest osteoclast count 
and vascularity 1 week after dental extractions, 
but bone turnover or bone resorption was higher 
in the group with ASCs without BMP-2, 
although these findings were not statistically 
significant. Further preclinical and clinical 
studies are needed to elucidate all of the 
implications of PRP and BMP-2 in ASC bone 
regeneration. 
We advocate local application of the MSCs 
(Cella et al., 2011) and not intravenous infusion 
(Kikuiri et al., 2010; Li et al., 2013). This 
application allows the benefits of ASCs to be 
concentrated in the area of interest. The 
fluorescence study revealed ASCs within the 
fibrous tissue and remodeled bone at the 
alveolar socket 7 days after their application, 
suggesting that ASCs are able to survive and 
disperse within the healing tissue in ZA-treated 
rats 1 week after dental extractions. Murine 
models have the disadvantage of a rapid 
metabolism and better healing than in humans, 
providing results that may be difficult to 
extrapolate to humans. Small animal models are 
indicated for the initial study of new therapies 
because of their costeffectiveness, easy 
handling, and fewer ethical and logistic issues, 
especially for long-lasting treatments, as in the 
case of BRONJ. No bone exposurewas archived 
in our study; this situationwas favored 
 
 
 
by the different treatments applied for BRONJ 
prevention and by the fact that no other drugs 
that may enhance osteonecrosis (e.g., 
corticoids or other immunosuppressive drugs) 
were administered, with the exception of ZA. 
Even with the limitations of this study, 
histologic osteonecrosis should be considered a 
relevant finding in animals with high 
metabolism and high bone turnover. Histologic 
osteonecrosis with no clinical bone exposure 
seems to be an initial phase of the disease, 
although histologic features are not included 
in the American Association of Oral and 
Maxillofacial Surgeons (AAOMS) definition of 
BRONJ in humans. The preventive effect of 
ASCs shown in this study provides new data for 
further advancing research on potential 
treatments for this severe disease in humans. 
5. Conclusion 
Despite the limitations of this experimental 
study performed in a limited number of animals, 
the study exemplifies preventive 
treatment of BRONJ after dental extractions in 
rats. As no other drugs were applied, the 
BRONJ-like lesions in our study are totally 
bisphosphonate dependent, which allows us to 
reach conclusions on the role of the studied 
treatments. We found that ASC-based 
treatments seem to prevent BRONJ in this high-
risk model, providing greater efficiency than 
mucosal flap with or without PRP. 
The combination of ASC and PRP appears to be 
synergistic, and the addition of BMP-2 could 
improve results even further. As all of 
these treatments are already in clinical use and 
as their safety profile has been widely studied, 
we believe that the combinations that we 
propose will soon be studied in clinical settings 
to determine their value in high-risk patients. 
Simultaneously, preclinical studies are needed 
to better describe the long-term results of these 
novel treatments and to obtain further details on 
the exact molecular mechanisms involved in the 
pathogenesis of BRONJ that could be prone to 
influence. 
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